LABT — Lakewood-Amedex Biotherapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2079272 ·
Last close
$0.77
Market Cap
$10.79M
52W High
$9.82
52W Low
$0.59
ADV30
3,239,317
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -886,750 | -923,291 | 196,343 | 11,709 | 3,037,991 |
| Dec 2025 | 0 | — | -712,060 | -744,918 | 481,598 | 236,400 | 2,446,135 |
| Sep 2025 | 0 | — | -1,880,317 | -1,907,159 | 985,118 | 658,410 | 2,251,434 |
| Mar 2025 | 0 | — | -542,609 | -539,617 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,914,001
Investing CF
$841,000
Financing CF
$325,000
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.76
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-54,274,421
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-3,999,835
Pretax Income TTM
$-4,114,985
Interest Exp TTM
$115,150
Analysts
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -3,772,370 | -3,847,637 | 481,598 | 2,446,135 | — | -1,944,698 |
| Dec 2024 | 0 | -4,026,820 | -4,855,405 | 1,070,581 | 660,970 | — | -5,723,322 |
| Dec 2023 | 0 | -8,636,719 | -8,281,960 | 6,893,904 | 2,335,577 | — | -6,816,114 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LNAI | Lunai Bioworks Inc. | $10.93M | $2.41 | — |
| KAYS | Kaya Holdings, Inc. | $10.98M | $0.02 | — |
| GELS | Gelteq Ltd | $10.60M | $0.99 | — |
| BFRI | Biofrontera Inc. | $11.07M | $0.87 | — |
| JUNS | JUPITER NEUROSCIENCES, INC. | $10.38M | $0.24 | — |
News headlines (Yahoo Finance, 1h cache)
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
2026-05-27 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers
2026-05-18 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3
2026-05-12 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
2026-04-28 11:33 · Yahoo
Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT"
2026-04-23 14:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.